



02-24-04

JFW 1647

PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**TRANSMITTAL
FORM**

(to be used for all correspondence after initial filing)

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/357,349	
	Filing Date	July 14, 1999	
	First Named Inventor	Geerts, et al.	
	Group Art Unit	1647	
	Examiner Name	Sharon L. Turner	
Total Number of Pages in This Submission	4	Attorney Docket Number	43962.010700

ENCLOSURES (check all that apply)

- ☐ Fee Transmittal Form
- ☐ Fee Attached
- ☐ Preliminary Amendment
- ☐ After Final
- ☐ Affidavits/declaration(s)

- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☐ Information Disclosure Statement

- ☐ Certified Copy of Priority Document(s)
- ☒ Amendment/Response to Notice to Comply with Sequence Listing Requirements under 37 CFR 1.821 - 1.825

- ☐ Response to Missing Parts under 37 CFR 1.52 or 1.53

- ☐ Assignment Papers (for an Application)
- ☒ Drawings (6 sheets of substitute drawings)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Associate Power of Attorney
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☒ Diskette 1 (electronic copy of the substitute sequence listing)

- ☐ After Allowance Communication to Group
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
- ☐ Proprietary Information
- ☐ Status Letter

- ☒ Other Enclosure(s)
(please identify below):

Paper copy of Substitute Sequence Listing; Statement in Support of CRF; copy of Notice to Comply dated January 21, 2004; Post card

Remarks

Sent by Express Mail No.: EK897085215US, deposited on February 23, 2004

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	Michel Morency, Reg. No. 50,183 Greenberg Traurig, LLP
Signature	
Date	February 23, 2004

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

#101985 V1



Appl. No.: 09/357,349

Response dated February 23, 2004

Response to Notice to Comply date January 21, 2004

Express Mail Label No.: EK897085215US

Date of Deposit: February 23, 2004

PL. NO. : 09/357,349
APPLICANT : Geerts, et al.
ASSIGNEE : Janssen Pharmaceutica N.V.
FILED : July 14, 1999
TITLE : NEUROTROPHIC GROWTH FACTOR
TC/A.U. : 1647
EXAMINER : Sharon L. Turner
DOCKET NO. : 43962-010700

Mail Stop Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

ATTN: Examiner Sharon L. Turner

AMENDMENT/RESPONSE

This paper is filed in response to a Notice to Comply with Requirements for Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, dated January 21, 2004. The present paper is due on or before Monday, February 23, 2004. This application claims benefit under 35 U.S.C. § 119 from United Kingdom Patent Application No. 9815283.8, filed on July 14, 1998, and is a continuation-in-part of U.S. Nonprovisional Application U.S.S.N. 09/327,668, filed on June 8, 1999, and a continuation-in-part of U.S. Nonprovisional Application U.S.S.N. 09/248,772, filed on February 12, 1999. The Commissioner is hereby authorized to charge any fees due with this submission, to Deposit Account No. 50-2678, Ref. No. 43962.010700.

Please amend the above-identified application as follows:

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Drawings begin on page 7 of this paper and include both an attached replacement and an annotated sheet showing changes.

Remarks begin on page 8 of this paper.

An **Appendix** including six (6) amended drawing figures is provided at page 9 of this paper.